Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | GAK | O14976 | 1/20 | 0.37 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.37 |
| ▸ | KIT | P10721 | 1/20 | 0.37 |
| ▸ | FLT3 | P36888 | 1/20 | 0.37 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.37 |
| ▸ | MARK1 | Q9P0L2 | 1/20 | 0.37 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.37 |
| ▸ | TNIK | Q9UKE5 | 7/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
| ▸ | APP | P05067 | 1/20 | 0.34 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.34 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.33 |
| ▸ | BRAF | P15056 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18558193 | 0.92 | RAB9A (0.50) | RAB9AGAKPDGFRBKITFLT3 | |
| SCHEMBL18558307 | 0.91 | RAB9A (0.43) | RAB9AGAKPDGFRBKITFLT3 | |
| SCHEMBL18558492 | 0.88 | RAB9A (0.46) | RAB9AGAKPDGFRBKITFLT3 | |
| SCHEMBL18558191 | 0.88 | RAB9A (0.46) | RAB9AGAKPDGFRBKITFLT3 | |
| SCHEMBL18558192 | 0.88 | RAB9A (0.46) | RAB9AGAKPDGFRBKITFLT3 | |
| SCHEMBL18558312 | 0.88 | RAB9A (0.46) | RAB9AGAKPDGFRBKITFLT3 | |
| SCHEMBL18558397 | 0.86 | RAB9A (0.44) | RAB9AGAKPDGFRBKITFLT3 | |
| SCHEMBL18558185 | 0.85 | RAB9A (0.42) | RAB9ATNIKCSNK2A2CSNK2A1MAPT | |
| SCHEMBL18558625 | 0.85 | RAB9A (0.46) | RAB9AGAKPDGFRBKITFLT3 | |
| SCHEMBL18558240 | 0.83 | RAB9A (0.52) | RAB9AGAKPDGFRBKITFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9932313-B2 | Pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof | LYCERA CORPORATION (US) | 2018-04-03 | — | — | US | disclosed |
| US-20170267643-A1 | PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2017-09-21 | — | — | US | disclosed |
| US-9580388-B2 | Pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof | LYCERA CORPORATION (US) | 2017-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267643-A1 | PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | ATP5F1A, ATP5F1D, ATP5ME | RAB9A 519/4885GAK 362/4885PDGFRB 4445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.